When Ideamensch asked Clay Siegall, the co-founder and CEO of Seattle Genetics, what prompted him to enter the cancer research field, he mentioned seeing the limited options that his father’s oncologists had at the time. Siegall went to George Washington University, where he obtained a doctorate in genetics, which enabled him to enter the research field. After working at Bristol-Myers Squibb’s Pharmaceutical Research Institute, Siegall started his own biotech company, which has a targeted drug that utilizes the first FDA approved antibody-drug conjugate technology that is used worldwide and numerous other drugs in the pipeline.
Siegall also told ideamensch that Seattle Genetics’ ADC collaborations helped the company grow. Roche, GlaxoSmithKline and Pfizer have licenses to use Seattle Genetics’ proprietary ADC technology, which gives oncologists more options to treat their patients.
In addition to serving as Seattle Genetics CEO and chairperson of the company’s Board of Directors, Siegall serves on the boards of Ultragenyx Pharmaceutical, Mirna Therapeutics and Alder BioPharmaceuticals. Siegall’s extensive pharmaceutical industry experience and his desire to meet the currently unmet needs of cancer patients makes him a welcome addition to the biotech companies’ boards. Talking about joining Mirna Therapeutics board, Siegall said, “I look forward to working with the team to advance its promising programs for patients in need.”
In 2016, under Siegall’s leadership, Seattle Genetics opened an office in Switzerland, as they are becoming a global, multi-product company that needs a base in Europe for potential future products, clinical trials and manufacturing. Currently, the company is running a number of clinical trials since it is Siegall’s vision to offer options for multiple types of cancers.
Clay Siegall has been recognized for his work numerous times, including receiving the 2013 University of Maryland Alumnus of the Year award and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year award.